Lysogene (FR0013233475 – LYS) (Paris: LYS) held its annual ordinary and extraordinary general meeting on June 26, 2020, in camera, under the chairmanship of Mrs. Karen Aiach, Chairman of the Board of Directors and Chief Executive Officer, without the physical presence of the shareholders.
With a quorum of 53.64%, the resolutions presented by the Board of Directors were adopted and in particular, the approval of the accounts for the year ended December 31, 2019, the remuneration policy applicable to the Chairman and Chief Executive Officer and to directors, as well as the delegations granted to the Board of Directors in financial matters.
The meeting also approved the renewal of the directorships of Karen Aiach, Philippe Goupit, Peter Lichtlen, David Schilansky, Mathieu Simon and Carole Deffez.
Details of the voting results on all resolutions will be available on the company’s website.
Lysogene is a biopharmaceutical company specializing in gene therapy targeting diseases of the central nervous system (CNS). The Company has acquired unique expertise to deliver CNS gene therapy safely and effectively to treat lysosomal storage disease and other CNS genetic diseases. Lysogene is currently conducting a Phase 2/3 clinical study in MPS IIIA, in partnership with Sarepta Therapeutics, Inc., and a Phase 1/3 clinical study in GM1 gangliosidosis is under preparation. Pursuant to the agreement between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold the exclusive commercial rights to LYS-SAF302 in the United States and in markets outside Europe, while Lysogene will maintain the commercial exclusivity of LYS -SAF302 in Europe. Lysogene is also working with an academic partner to define the strategy for developing a treatment for Fragile X syndrome, a genetic disorder linked to autism. www.lysogene.com